Our study shows that patients with anaemia after acute non‐variceal GIB respond significantly better to iv FCM given at an Hb‐ and body weight‐depending dose scheme (as per SmPC) compared with high‐dose oral FeSulf. The gene discussed is GSTM1; the disease is anemia.